Abcam pharma deals with Pfizer, a big company, entering into a supply and licensing agreement for biological compounds.
As part of the terms of the pharma deals agreement, Abcam’s Biochemicals division will supply a range of authentic Pfizer compounds for use as pre-clinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.
The pharma deals agreement covers a broad group of Pfizer compounds including atorvastatin, doxorubicin, nifedipine and bosutinib, all of which are widely used in pre-clinical research.
The Pfizer research compounds and Abcam Biochemicals range will support pre-clinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance as part of the pharma deals.
Abcam plc is a provider of protein research tools and services, with an unrivalled range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Report: Partnering Deals and Alliances with Pfizer
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity